AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV
Executive Summary
FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.
You may also be interested in...
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.
AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.